Search Results - "Almaden, Chau"

Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance by Schwartz, Phillip A., Kuzmic, Petr, Solowiej, James, Bergqvist, Simon, Bolanos, Ben, Almaden, Chau, Nagata, Asako, Ryan, Kevin, Feng, Junli, Dalvie, Deepak, Kath, John C., Xu, Meirong, Wani, Revati, Murray, Brion William

“…Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chemical reactivity in overall potency are…”
Get full text

Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors by Niessen, Sherry, Dix, Melissa M, Barbas, Sabrina, Potter, Zachary E, Lu, Shuyan, Brodsky, Oleg, Planken, Simon, Behenna, Douglas, Almaden, Chau, Gajiwala, Ketan S, Ryan, Kevin, Ferre, RoseAnn, Lazear, Michael R, Hayward, Matthew M, Kath, John C, Cravatt, Benjamin F

“…Patients with non-small cell lung cancers that have kinase-activating epidermal growth factor receptor (EGFR) mutations are highly responsive to first-…”
Get more information

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195) by Cheng, Hengmiao, Orr, Suvi T M, Bailey, Simon, Brooun, Alexei, Chen, Ping, Deal, Judith G, Deng, Yali L, Edwards, Martin P, Gallego, Gary M, Grodsky, Neil, Huang, Buwen, Jalaie, Mehran, Kaiser, Stephen, Kania, Robert S, Kephart, Susan E, Lafontaine, Jennifer, Ornelas, Martha A, Pairish, Mason, Planken, Simon, Shen, Hong, Sutton, Scott, Zehnder, Luke, Almaden, Chau D, Bagrodia, Shubha, Falk, Matthew D, Gukasyan, Hovhannes J, Ho, Caroline, Kang, Xiaolin, Kosa, Rachel E, Liu, Ling, Spilker, Mary E, Timofeevski, Sergei, Visswanathan, Ravi, Wang, Zhenxiong, Meng, Fanxiu, Ren, Shijian, Shao, Li, Xu, Feng, Kath, John C

“…The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway is a frequently dysregulated pathway in human cancer, and PI3Kα is…”
Get full text

Effect of PF-04217329 a prodrug of a selective prostaglandin EP2 agonist on intraocular pressure in preclinical models of glaucoma by Prasanna, Ganesh, Carreiro, Samantha, Anderson, Scott, Gukasyan, Hovhannes, Sartnurak, Soisurin, Younis, Husam, Gale, David, Xiang, Cathie, Wells, Peter, Dinh, Dac, Almaden, Chau, Fortner, Jay, Toris, Carol, Niesman, Michael, Lafontaine, Jennifer, Krauss, Achim

Get full text

Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models by Prasanna, Ganesh, Fortner, Jay, Xiang, Cathie, Zhang, Eric, Carreiro, Samantha, Anderson, Scott, Sartnurak, Soisurin, Wu, Grace, Gukasyan, Hovhannes, Niesman, Michael, Nair, Sajiv, Rui, Eugene, Lafontaine, Jennifer, Almaden, Chau Doan, Wells, Peter, Krauss, Achim

“…Prostaglandins are widely used to lower intraocular pressure (IOP) as part of the treatment regimen for glaucoma. While FP and EP2 agonists are known to lower…”
Get full text

Discovery of N‑((3R,4R)‑4-Fluoro-1-(6-((3-methoxy-1-methyl‑1H‑pyrazol-4-yl)amino)-9-methyl‑9H‑purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR by Planken, Simon, Behenna, Douglas C, Nair, Sajiv K, Johnson, Theodore O, Nagata, Asako, Almaden, Chau, Bailey, Simon, Ballard, T. Eric, Bernier, Louise, Cheng, Hengmiao, Cho-Schultz, Sujin, Dalvie, Deepak, Deal, Judith G, Dinh, Dac M, Edwards, Martin P, Ferre, Rose Ann, Gajiwala, Ketan S, Hemkens, Michelle, Kania, Robert S, Kath, John C, Matthews, Jean, Murray, Brion W, Niessen, Sherry, Orr, Suvi T. M, Pairish, Mason, Sach, Neal W, Shen, Hong, Shi, Manli, Solowiej, James, Tran, Khanh, Tseng, Elaine, Vicini, Paolo, Wang, Yuli, Weinrich, Scott L, Zhou, Ru, Zientek, Michael, Liu, Longqing, Luo, Yiqin, Xin, Shuibo, Zhang, Chengyi, Lafontaine, Jennifer

“…Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as…”
Get full text

Discovery of 1‑{(3R,4R)‑3-[({5-Chloro-2-[(1-methyl‑1H‑pyrazol-4-yl)amino]‑7H‑pyrrolo[2,3‑d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants by Cheng, Hengmiao, Nair, Sajiv K, Murray, Brion W, Almaden, Chau, Bailey, Simon, Baxi, Sangita, Behenna, Doug, Cho-Schultz, Sujin, Dalvie, Deepak, Dinh, Dac M, Edwards, Martin P, Feng, Jun Li, Ferre, Rose Ann, Gajiwala, Ketan S, Hemkens, Michelle D, Jackson-Fisher, Amy, Jalaie, Mehran, Johnson, Ted O, Kania, Robert S, Kephart, Susan, Lafontaine, Jennifer, Lunney, Beth, Liu, Kevin K.-C, Liu, Zhengyu, Matthews, Jean, Nagata, Asako, Niessen, Sherry, Ornelas, Martha A, Orr, Suvi T. M, Pairish, Mason, Planken, Simon, Ren, Shijian, Richter, Daniel, Ryan, Kevin, Sach, Neal, Shen, Hong, Smeal, Tod, Solowiej, Jim, Sutton, Scott, Tran, Khanh, Tseng, Elaine, Vernier, William, Walls, Marlena, Wang, Shuiwang, Weinrich, Scott L, Xin, Shuibo, Xu, Haiwei, Yin, Min-Jean, Zientek, Michael, Zhou, Ru, Kath, John C

“…First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately,…”
Get full text

Effect of PF-04217329 a prodrug of a selective prostaglandin EP 2 agonist on intraocular pressure in preclinical models of glaucoma by Prasanna, Ganesh, Carreiro, Samantha, Anderson, Scott, Gukasyan, Hovhannes, Sartnurak, Soisurin, Younis, Husam, Gale, David, Xiang, Cathie, Wells, Peter, Dinh, Dac, Almaden, Chau, Fortner, Jay, Toris, Carol, Niesman, Michael, Lafontaine, Jennifer, Krauss, Achim

“…Better control of intraocular pressure (IOP) is the most effective way to preserve visual field function in glaucomatous patients. While prostaglandin FP…”
Get full text

Discovery of N -((3 R ,4 R )-4-Fluoro-1-(6-((3-methoxy-1-methyl-1 H -pyrazol-4-yl)amino)-9-methyl-9 H -purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR by Planken, Simon, Behenna, Douglas C., Nair, Sajiv K., Johnson, Theodore O., Nagata, Asako, Almaden, Chau, Bailey, Simon, Ballard, T. Eric, Bernier, Louise, Cheng, Hengmiao, Cho-Schultz, Sujin, Dalvie, Deepak, Deal, Judith G., Dinh, Dac M., Edwards, Martin P., Ferre, Rose Ann, Gajiwala, Ketan S., Hemkens, Michelle, Kania, Robert S., Kath, John C., Matthews, Jean, Murray, Brion W., Niessen, Sherry, Orr, Suvi T. M., Pairish, Mason, Sach, Neal W., Shen, Hong, Shi, Manli, Solowiej, James, Tran, Khanh, Tseng, Elaine, Vicini, Paolo, Wang, Yuli, Weinrich, Scott L., Zhou, Ru, Zientek, Michael, Liu, Longqing, Luo, Yiqin, Xin, Shuibo, Zhang, Chengyi, Lafontaine, Jennifer

Get full text

Abstract 5043: Effects of a novel PI3 kinase/mTOR inhibitor on proliferation and pAKT signaling in canine lymphoma by Berlinski, Pamela, Kamerling, Steven, Colhoun, Heather, Forester, Nancy, Marotti, Keith, Bagrodia, Shubha, Cheng, Henry, Pascual, Bernadette, Yuan, Jing, Chen, Jeffrey, Engebretse, Jon, Rafidi, Kristina, Zhang, Eric, Wang, Sophie, Zou, Aihua, Carlson, Tom, Almaden, Chau, Barker, John, Gehring, Michael, Nguyen, Leslie, Shen, Andrea, Hemkens, Michelle, McHarg, Aileen, Sun, Shaoxian, Carley, William W.

“…Abstract PF-04691503 is a dual inhibitor of both PI3K and mTOR, inhibits PI3K signaling in cancer cell lines, and exhibits in vitro and in vivo…”
Get full text

Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma by Prasanna, Ganesh, Carreiro, Samantha, Anderson, Scott, Gukasyan, Hovhannes, Sartnurak, Soisurin, Younis, Husam, Gale, David, Xiang, Cathie, Wells, Peter, Dinh, Dac, Almaden, Chau, Fortner, Jay, Toris, Carol, Niesman, Michael, Lafontaine, Jennifer, Krauss, Achim

“…Better control of intraocular pressure (IOP) is the most effective way to preserve visual field function in glaucomatous patients. While prostaglandin FP…”
Get full text